ibrutinib resistance

Ibrutinib resistance occurs when certain cancer cells adapt and no longer respond to the drug that was initially effective. Ibrutinib is designed to block proteins that help cancer cells grow and survive. Over time, some cancer cells find ways to bypass this blockade, either by mutating the target proteins or activating alternative pathways, allowing the disease to progress despite treatment. Understanding this resistance helps researchers develop new strategies to overcome it, such as combining drugs or creating new therapies, to better control or eradicate the cancer.